PASylation of Murine Leptin Leads to Extended Plasma Half-Life and Enhanced in Vivo Efficacy
about
Leptin applications in 2015: what have we learned about leptin and obesity?Aminoglycosides, but not PTC124 (Ataluren), rescue nonsense mutations in the leptin receptor and in luciferase reporter genes.Protein-polymer conjugation-moving beyond PEGylation.Reprogramming the body weight set point by a reciprocal interaction of hypothalamic leptin sensitivity and Pomc gene expression reverts extreme obesityHalf-life extended biotherapeutics.Materials and methods for delivery of biological drugs.Half-Life Extension of Biopharmaceuticals using Chemical Methods: Alternatives to PEGylation.Anti-PEG antibodies in the clinic: Current issues and beyond PEGylation.The polypeptide biophysics of proline/alanine-rich sequences (PAS): Recombinant biopolymers with PEG-like properties.Development of a novel nano-sized anti-VEGFA nanobody with enhanced physicochemical and pharmacokinetic properties.Intranasal delivery of N-terminal modified leptin-pluronic conjugate for treatment of obesity.Treatment of diet-induced lipodystrophic C57BL/6J mice with long-acting PASylated leptin normalises insulin sensitivity and hepatic steatosis by promoting lipid utilisation.PASylation technology improves recombinant interferon-β1b solubility, stability, and biological activity.A platform for discovery of functional cell-penetrating peptides for efficient multi-cargo intracellular delivery
P2860
Q28087233-A2339A98-800F-424D-93C7-121D3CF397B1Q33681878-E980A7CB-1869-4224-922B-812B489C645EQ36220152-87102C1B-F2DD-4A09-80A0-3A691CE64BCCQ37278847-79446C46-8C36-4F47-ABC4-889F8FD7844FQ38770067-2E0DDC61-AAFC-4579-90F7-FACD20481B9CQ38987392-CFF1A319-0E54-409E-9F98-890F61C2EC7BQ38989309-111D28E2-F592-4466-AE3C-4E5F642D72D9Q47102857-413DC932-D0B2-4C77-BE85-F5E89AE07AC8Q47596433-9EFFC121-9860-4278-A573-8B2B26F1171FQ47753474-CAF88D44-8EC2-4563-BE33-7AA876CB0091Q47933830-D066BA51-3096-441E-9002-15A3911AE770Q50801472-78CFCC61-0C01-4F6D-9158-76D0EDA90D83Q51069046-74E19CC0-D207-4306-8C64-6C331FD55EA7Q57524985-A5B8CAA7-E4D9-406D-B8F9-A1384BCCF488
P2860
PASylation of Murine Leptin Leads to Extended Plasma Half-Life and Enhanced in Vivo Efficacy
description
im April 2015 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована у квітні 2015
@uk
name
PASylation of Murine Leptin Le ...... and Enhanced in Vivo Efficacy
@en
PASylation of Murine Leptin Le ...... and Enhanced in Vivo Efficacy
@nl
type
label
PASylation of Murine Leptin Le ...... and Enhanced in Vivo Efficacy
@en
PASylation of Murine Leptin Le ...... and Enhanced in Vivo Efficacy
@nl
prefLabel
PASylation of Murine Leptin Le ...... and Enhanced in Vivo Efficacy
@en
PASylation of Murine Leptin Le ...... and Enhanced in Vivo Efficacy
@nl
P2093
P50
P356
P1476
PASylation of Murine Leptin Le ...... and Enhanced in Vivo Efficacy
@en
P2093
Florian Bolze
Katrin Seyfarth
Sarah Schneider
P304
P356
10.1021/MP5007147
P407
P577
2015-04-10T00:00:00Z